NASDAQ:AGLEAeglea Bio Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aeglea Bio Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.75 +0.24 (+3.69 %) (As of 08/13/2020 04:00 PM ET) Add Compare Share Today's Range$6.53Now: $6.75▼$6.8550-Day Range$6.51MA: $8.25▼$10.5052-Week Range$3.50Now: $6.75▼$11.38Volume245,800 shsAverage Volume189,171 shsMarket Capitalization$301.05 millionP/E RatioN/ADividend YieldN/ABeta1.89 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers. Its preclinical pipeline products comprise AEB4104, a recombinant human enzyme that degrades the amino acid homocysteine and its oxidized form homocysteine; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB3103, an engineered human enzyme that targets the degradation of the amino acid cysteine/cysteine; and AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine. Aeglea BioTherapeutics, Inc. has a clinical collaboration agreement with Merck to evaluate the combination of pegzilarginase with Merck's anti-PD1 therapy, pembrolizumab, for the treatment of patients with small cell lung cancer. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAeglea Bio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.33, Aeglea Bio Therapeutics has a potential upside of 97.5% from its current price of $6.75.Amount of Analyst CoverageAeglea Bio Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAeglea Bio Therapeutics has received 238 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAeglea Bio Therapeutics has received 195 “underperform” votes. (Add your “underperform” vote.)Community SentimentAeglea Bio Therapeutics has received 54.97% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aeglea Bio Therapeutics and other stocks. Vote “Outperform” if you believe AGLE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AGLE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAeglea Bio Therapeutics does not currently pay a dividend.Dividend GrowthAeglea Bio Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aeglea Bio Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 13.70% of the stock of Aeglea Bio Therapeutics is held by insiders.Percentage Held by Institutions46.08% of the stock of Aeglea Bio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aeglea Bio Therapeutics are expected to decrease in the coming year, from ($1.71) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aeglea Bio Therapeutics is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aeglea Bio Therapeutics is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAeglea Bio Therapeutics has a P/B Ratio of 3.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.44 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGLE Previous Symbol CUSIPN/A CIK1636282 Webwww.aegleabio.com Phone512-942-2935Debt Debt-to-Equity Ratio0.11 Current Ratio3.17 Quick Ratio3.17Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.89 million Price / Sales77.39 Cash FlowN/A Price / Cash FlowN/A Book Value$2.07 per share Price / Book3.26Profitability EPS (Most Recent Fiscal Year)($2.45) Net Income$-78,250,000.00 Net MarginsN/A Return on Equity-136.65% Return on Assets-100.64%Miscellaneous Employees61 Outstanding Shares44,600,000Market Cap$301.05 million Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $6.75 +0.24 (+3.69 %) (As of 08/13/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AGLE News and Ratings via Email Sign-up to receive the latest news and ratings for AGLE and its competitors with MarketBeat's FREE daily newsletter. Aeglea Bio Therapeutics (NASDAQ:AGLE) Frequently Asked Questions How has Aeglea Bio Therapeutics' stock been impacted by Coronavirus (COVID-19)? Aeglea Bio Therapeutics' stock was trading at $5.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AGLE shares have increased by 25.5% and is now trading at $6.75. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Aeglea Bio Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea Bio Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aeglea Bio Therapeutics. When is Aeglea Bio Therapeutics' next earnings date? Aeglea Bio Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Aeglea Bio Therapeutics. How were Aeglea Bio Therapeutics' earnings last quarter? Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) released its quarterly earnings data on Monday, August, 10th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.43) by $0.03. View Aeglea Bio Therapeutics' earnings history. What price target have analysts set for AGLE? 3 Wall Street analysts have issued twelve-month target prices for Aeglea Bio Therapeutics' shares. Their forecasts range from $11.00 to $17.00. On average, they anticipate Aeglea Bio Therapeutics' stock price to reach $13.33 in the next year. This suggests a possible upside of 97.5% from the stock's current price. View analysts' price targets for Aeglea Bio Therapeutics. Has Aeglea Bio Therapeutics been receiving favorable news coverage? News headlines about AGLE stock have trended negative this week, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aeglea Bio Therapeutics earned a daily sentiment score of -2.4 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Aeglea Bio Therapeutics. Are investors shorting Aeglea Bio Therapeutics? Aeglea Bio Therapeutics saw a increase in short interest in June. As of June 30th, there was short interest totaling 1,140,000 shares, an increase of 145.8% from the June 15th total of 463,700 shares. Based on an average daily trading volume, of 312,300 shares, the short-interest ratio is currently 3.7 days. View Aeglea Bio Therapeutics' Short Interest. Who are some of Aeglea Bio Therapeutics' key competitors? Some companies that are related to Aeglea Bio Therapeutics include Akcea Therapeutics (AKCA), Kura Oncology (KURA), Kiniksa Pharmaceuticals (KNSA), Arvinas (ARVN), Arcus Biosciences (RCUS), Constellation Pharmaceuticals (CNST), Karyopharm Therapeutics (KPTI), Theravance Biopharma (TBPH), Phathom Pharmaceuticals (PHAT), Humanigen (HGEN), Nabriva Therapeutics (NBRV), Akero Therapeutics (AKRO), I-Mab (ARQT), Enanta Pharmaceuticals (ENTA) and Stoke Therapeutics (STOK). View all competitors. What other stocks do shareholders of Aeglea Bio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea Bio Therapeutics investors own include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Dicerna Pharmaceuticals (DRNA), Kura Oncology (KURA), Aduro BioTech (ADRO), Agile Therapeutics (AGRX), Axsome Therapeutics (AXSM), Corbus Pharmaceuticals (CRBP), ImmunoGen (IMGN) and Myovant Sciences (MYOV). Who are Aeglea Bio Therapeutics' key executives? Aeglea Bio Therapeutics' management team includes the following people: Dr. Anthony G. Quinn M.B Ch.B., Ph.D., FRCP, Pres, CEO & Director (Age 57)Mr. Charles N. York II, CFO & VP (Age 42)Dr. James E. Wooldridge M.D., Chief Medical Officer (Age 53)Dr. Leslie Sloan Ph.D., Chief Operating Officer (Age 48)Mr. Eugene Sackett, VP of HR When did Aeglea Bio Therapeutics IPO? (AGLE) raised $60 million in an initial public offering (IPO) on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager. What is Aeglea Bio Therapeutics' stock symbol? Aeglea Bio Therapeutics trades on the NASDAQ under the ticker symbol "AGLE." Who are Aeglea Bio Therapeutics' major shareholders? Aeglea Bio Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Marshall Wace LLP (2.80%), Goldman Sachs Group Inc. (1.02%), Assenagon Asset Management S.A. (0.75%), University of Texas Texas AM Investment Managment Co. (0.63%), Ritholtz Wealth Management (0.39%) and Russell Investments Group Ltd. (0.15%). Company insiders that own Aeglea Bio Therapeutics stock include Aaron Schuchart and Anthony G Quinn. View institutional ownership trends for Aeglea Bio Therapeutics. Which major investors are selling Aeglea Bio Therapeutics stock? AGLE stock was sold by a variety of institutional investors in the last quarter, including Ritholtz Wealth Management, and University of Texas Texas AM Investment Managment Co.. View insider buying and selling activity for Aeglea Bio Therapeutics. Which major investors are buying Aeglea Bio Therapeutics stock? AGLE stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Assenagon Asset Management S.A., Goldman Sachs Group Inc., New York State Common Retirement Fund, Franklin Street Advisors Inc. NC, Trexquant Investment LP, ProShare Advisors LLC, and SG Americas Securities LLC. View insider buying and selling activity for Aeglea Bio Therapeutics. How do I buy shares of Aeglea Bio Therapeutics? Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aeglea Bio Therapeutics' stock price today? One share of AGLE stock can currently be purchased for approximately $6.75. How big of a company is Aeglea Bio Therapeutics? Aeglea Bio Therapeutics has a market capitalization of $301.05 million and generates $3.89 million in revenue each year. The biotechnology company earns $-78,250,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis. Aeglea Bio Therapeutics employs 61 workers across the globe. What is Aeglea Bio Therapeutics' official website? The official website for Aeglea Bio Therapeutics is www.aegleabio.com. How can I contact Aeglea Bio Therapeutics? Aeglea Bio Therapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-942-2935 or via email at [email protected] This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
